Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Inmune Bio, Inc.

Get SEC filing alerts via email and in your feed for Inmune Bio, Inc.

INMB

Inmune Bio, Inc.

About Inmune Bio, Inc.

INmune Bio Inc. develops immunotherapies targeting innate immune dysfunction to treat cancer, neurodegenerative, and inflammatory diseases. Its core platforms include INKmune, an NK cell-based cancer therapy; XPro1595, a TNF inhibitor for Alzheimer's and neuroinflammation; and CORDStrom, a stem cell product for skin disorders. The company focuses on innovative biologics, regulatory pathways, and strategic collaborations to address unmet medical needs in global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Inmune Bio, Inc.

1
1
Inmune Bio, Inc. INmune Bio Reports $5.4 Million Net Loss in Q1 2026, No Revenue Generated

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Inmune Bio, Inc. INmune Bio Reports $45.9 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Inmune Bio, Inc. Inmune Bio Reports Q3 2025 Financial Results with Improved Net Loss of $6.5 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Inmune Bio, Inc. INmune Bio Reports $24.5 Million Net Loss in Q2 2025, Driven by Impairment Charge

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Inmune Bio, Inc. INmune Bio Reports Revenue Increase and Narrowed Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Inmune Bio, Inc. INmune Bio Reports $42.1 Million Net Loss and Decreased Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Inmune Bio, Inc. INmune Bio Reports Significant Financial Challenges, Net Loss of $32.9 Million in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments